Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Res
Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile. As the most commonly prescribed drug in this class, semaglutide is effective in both diabetic and non-diabetic individuals. However, treatment responses vary significantly, with non-
| Condition(s) | Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Insulin Sensitivity/Resistance, Semaglutide |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile. As the most commonly prescribed drug in this class, semaglutide is effective in both diabetic and non-diabetic individuals. However, treatment responses vary significantly, with non-diabetic individuals typically experiencing better weight loss outcomes. Despite this, up to 10% of non-diabetic individuals show little or no response to treatment, and the reasons for this variability remain unclear. The TRIM-IR study aims to investigate the role of insulin resistance (IR) in weight loss outcomes among non-diabetic obese individuals receiving semaglutide. This single-center, observational study will assess the impact of IR on weight loss, body composition, |
| Who can participate | Inclusion Criteria: 1. Age between 18 and 60 years 2. BMI 30 - 40 kg/m2 a. Participants must meet the eligibility criteria for coverage under the KVG (Federal Health Insurance Act) and the Specialties List, which include a weight-related comorbidity (arterial hypertension, dyslipidemia) for participants with a BMI of 30- 35 kg/m2 3. Planned therapy with semaglutide as a weight loss intervention 4. No known presence of a diabetic state 5. Ability to understand and sign a Patient Information and Consent Form Exclusion Criteria: 1. Pregnancy or active breast feeding 1. Therapy with semaglutide is not approved for use during pregnancy or while breastfeeding, as its safety and efficacy in these conditions have not been established. 2. Pregnancy is an exclusion criterion for the planned investig |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Lead sponsor | ETH Zurich |
| Locations | Aarau, Canton of Aargau, Switzerland |
| Start date | 2025-03-15 |
| NCT ID | NCT06856291 |
| Official listing | https://clinicaltrials.gov/study/NCT06856291 |